A CITF-funded study published in AIDS, demonstrated that fourth COVID-19 vaccine doses, irrespective of whether they are monovalent or bivalent, benefit people living with HIV (PLWH) who receive anti-retroviral therapies (ART), including those who have already experienced a SARS-CoV-2 infection.
A partially CITF-funded study published in Cell Reports demonstrated that people infected with SARS-CoV-2, whether before or after vaccination, have better antibody responses than vaccinated individuals who were never infected (SARS-CoV-2 naïve).
A partially CITF-funded, study, published in Vaccines, demonstrated that hybrid immunity, generated by vaccination and recent infection, induces higher humoral responses than vaccination alone against ancestral and Omicron variant BA.5 subvariant BQ.1.1 SARS-CoV-2 strains, regardless of which mRNA vaccine is administered.
In a CITF-funded study published in Vaccines, Dr. Marc-André Langlois (University of Ottawa) found that adjuvanted protein vaccines administered intranasally can elicit strong both systemic and mucosal antibody responses against SARS-CoV-2 variants in mice.
In a letter published in Gut, Drs. Genelle Healey, Bruce Vallance and CITF-funded researcher Dr. Pascal Lavoie (University of British Columbia) and their team identified a link between the composition of one’s gut microbiota and COVID-19 vaccine-induced immunity.
A CITF-funded study published in PLoS One, led by Drs. Marc-André Langlois and Allyson MacLean (University of Ottawa), demonstrated that agroinfiltration, a method to generate proteins in plants, could be used to produce the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
In a study partially funded by the CITF and published in Cell Reports, Drs. Andrés Finzi (Université de Montréal) and Renée Bazin (Héma-Québec) showed that a third vaccine dose elicited strong antibody responses regardless of the interval between the first and second doses.
A paper published in NPJ Vaccines by CITF-funded researcher Dr. Michael Grant (Memorial University of Newfoundland) shows that, in a group of individuals who had been infected with SARS-CoV-2, the immune response induced by the subsequent rounds of vaccination was stronger when the COVID-19 symptoms were more severe.
Live viral neutralizing antibody titers are widely accepted as a good measure of immunity, yet conducting the assays are time-consuming and laborious making them suboptimal for population level measurements.
A new study, published in Microbiology Spectrum from the CITF-funded Canadian Blood Services (CBS) team led by Drs. Sheila O’Brien and Steven Drews, characterizes the ability of a new immunoassay to specify the concentration of neutralizing antibodies against SARS-CoV-2 in blood plasma.